CRISPR Therapeutics AG (CRSP) Change in Receivables (2016 - 2025)

CRISPR Therapeutics AG has disclosed Change in Receivables across 10 years of filings, most recently posting -$25.0 million for Q1 2025.

• Change in Receivables for Q1 2025 came in at -$25.0 million, up 87.5% year-over-year; the trailing twelve-month figure through Dec 2025 was -$25.0 million (up 85.71% YoY), and the FY2025 annual result was -$25.0 million, up 85.71% from the prior year.
• Change in Receivables came in at -$25.0 million for Q1 2025 at CRISPR Therapeutics AG, down from $25.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $200.0 million in Q4 2023 to a low of -$200.0 million in Q1 2024.
• The 5-year median for Change in Receivables is -$17000.0 (2022), against an average of -$11076.9.
• Peak annual rise in Change in Receivables reached 408263.27% in 2023, while the deepest fall reached 411664.71% in 2023.
• CRISPR Therapeutics AG's Change in Receivables stood at $153000.0 in 2021, then tumbled by 132.03% to -$49000.0 in 2022, then jumped by 408263.27% to $200.0 million in 2023, then tumbled by 87.5% to $25.0 million in 2024, then slumped by 200.0% to -$25.0 million in 2025.
• The last three Change in Receivables figures came in at -$25.0 million (Q1 2025), $25.0 million (Q4 2024), and -$200.0 million (Q1 2024), per Business Quant data.